Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial – LANCET REGIONAL HEALTH-EUROPE

Corominas, J; Garriga, C; Prenafeta, A; Moros, A; Cañete, M; Barreiro, A; González-González, L; Madrenas, L; Güell, I; Clotet, B; Izquierdo-Useros, N; Raïch-Regué, D; Gallemí, M; Blanco, J; Pradenas, E; Trinité, B; Prado, JG; Blanch-Lombarte, O; Pérez-Caballero, R; Plana, M; Esteban, I; Pastor-Quiñones, C; Núñez-Costa, X; Abu Taleb, R; McSkimming, P; Soriano, A; Nava, J; Anagua, JO; Ramos, R; Lluch, RM; Comes, AC; Romero, SO; Gomez, XM; Sans-Pola, C; Moltó, J; Benet, S; Bailón, L; Arribas, JR; Borobia, AM; Parada, JQ; Navarro-Pérez, J; Giner, MJF; Lucas, RO; Jiménez, MDV; Compán, SO; Alvarez-Mon, M; Troncoso, D; Arana-Arri, E; Meijide, S; Imaz-Ayo, N; García, PM; Martínez, SD; Fernández, SR; Prat, T; Torroella, E; Ferrer, L – 2023 – 10.1016/j.lanepe.2023.100613